FDA 483 - Hanlim Pharm Co., Ltd. - February 06, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of HanLim Pharm Co., Ltd. in Yonginsi Ceoin-gu, Korea, a sterile OTC drug manufacturer, revealed multiple significant deficiencies. These included failures in aseptic processing procedures, inadequate validation of sterilization processes, and insufficient laboratory controls for product specifications. The firm also exhibited issues with data integrity, personnel training for critical operations, and environmental monitoring in aseptic areas, indicating a broad lack of control over manufacturing processes designed to ensure product sterility and quality.
ID · 22b865c6-cf21-4758-84f3-182b1bbd11c9